ArticleHead and neck pathology2025
Nodal Metastasis in Low Grade Salivary Gland Carcinoma: A Retrospective Analysis of Incidence, Histologic Spectrum and Outcome.
Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLymph node metastasis is an adverse pathologic feature that often necessitates post-operative adjuvant radiation therapy or concurrent chemoradiation for salivary gland carcinoma (SGC). While regional metastasis is more common in high grade SGCs, it is rare in low grade (LG) SGCs.
methodsIn this retrospective study, we conducted a detailed review of a retrospective cohort of 543 LG-SGCs. Nodal metastasis at presentation and regional recurrence were identified in 7% (n = 38) and 3% (n = 14) of LG-SGCs respectively. The incidence of nodal metastasis varied by tumor histologic subtype, ranging from 0% for epithelial-myoepithelial carcinoma to 10% for polymorphous adenocarcinoma. Compared with LG-SGCs without nodal metastasis, those with regional metastasis were associated with a significantly higher frequency of pT4 disease, larger tumor size, lymphovascular invasion, and perineural invasion. However, clinical outcomes did not differ significantly between the two groups. The 5-year disease-specific survival was 100% and 99% respectively for pN + and pNx/pN0 groups, while the 5-year disease-free survival was 82% and 93% respectively. Among the LG-SGCs that developed regional recurrence to neck lymph nodes, the time between primary resection and recurrent disease ranged from 6 to 233 months (median = 64 months).
conclusionNodal metastasis, though rare, occurs in 7% of patients with LG-SGCs at the time of diagnosis and in 3% as a recurrent disease. It is associated with pT4 disease, larger tumor size, perineural and lymphovascular invasion but does not appear to significantly impact clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.